Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
Backed by an $8.4 billion international licensing deal with Bristol Myers Squibb, Biokin’s groundbreaking dual-target therapy…
Chinese innovative drug makers step onto the global stage through licensing and foreign co-co deals
By Da Cheung In 2025, China’s innovative pharmaceutical companies quietly crossed a historic threshold, overtaking the…
Latest
- Han’s CNC rides AI infrastructure boom, but expansion brings new risks
- China demonstrates novel net-catch rocket recovery system as it races to close the gap with SpaceX
- China turns to molten salt to tackle renewable energy storage bottlenecks in the national grid
- Dramatic slowdown in China’s range-extended electric vehicle market raises concerns over Xiaomi’s strategy
- Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
